Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study.

Kirenga BJ, Levin J, Ayakaka I, Worodria W, Reilly N, Mumbowa F, Nabanjja H, Nyakoojo G, Fennelly K, Nakubulwa S, Joloba M, Okwera A, Eisenach KD, McNerney R, Elliott AM, Mugerwa RD, Smith PG, Ellner JJ, Jones-López EC.

PLoS One. 2014 Mar 7;9(3):e90614. doi: 10.1371/journal.pone.0090614. eCollection 2014.

2.

Household ventilation and tuberculosis transmission in Kampala, Uganda.

Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED.

Int J Tuberc Lung Dis. 2013 Jun;17(6):764-70. doi: 10.5588/ijtld.12.0681.

PMID:
23676159
3.

Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis.

Fennelly KP, Jones-López EC, Ayakaka I, Kim S, Menyha H, Kirenga B, Muchwa C, Joloba M, Dryden-Peterson S, Reilly N, Okwera A, Elliott AM, Smith PG, Mugerwa RD, Eisenach KD, Ellner JJ.

Am J Respir Crit Care Med. 2012 Sep 1;186(5):450-7. doi: 10.1164/rccm.201203-0444OC. Epub 2012 Jul 12.

4.

A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, Mupere E, Mugyenyi P, Boom WH, Mugerwa RD, Havlir DV, Whalen CC.

J Infect Dis. 2011 Sep 15;204(6):884-92. doi: 10.1093/infdis/jir503.

5.

Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.

Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, Van Leth F, Mayanja-Kizza H, Kestens L, Mugerwa RD, Reiss P, Colebunders R; TB-IRIS Study Group.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):32-7. doi: 10.1097/QAI.0b013e3182255dc2.

PMID:
21654499
6.

Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Jones-López EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R, Elliott AM, Ellner JJ, Smith PG, Mugerwa RD.

PLoS Med. 2011 Mar;8(3):e1000427. doi: 10.1371/journal.pmed.1000427. Epub 2011 Mar 15.

7.

Product Development Priorities.

Mahmoud A, Danzon PM, Barton JH, Mugerwa RD.

In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): World Bank; 2006. Chapter 6.

8.

Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda.

Bark CM, Morrison CS, Salata RA, Byamugisha JK, Katalemwa NH, Mugerwa RD, Mukasa JB, Musoke RN, Nankya-Mutyoba J, Rwambuya S, Walker CJ, Johnson JL.

Int J Tuberc Lung Dis. 2010 Dec;14(12):1647-9.

PMID:
21144254
9.

Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW.

J Clin Microbiol. 2010 Dec;48(12):4370-6. doi: 10.1128/JCM.00757-10. Epub 2010 Oct 6.

10.

Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.

Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED.

Int J Tuberc Lung Dis. 2010 Oct;14(10):1295-302.

11.

Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count.

Chamie G, Charlebois ED, Srikantiah P, Walusimbi-Nanteza M, Mugerwa RD, Mayanja H, Okwera A, Whalen CC, Havlir DV.

Clin Infect Dis. 2010 Aug 1;51(3):359-62. doi: 10.1086/654799.

12.

Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.

Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH; Uganda-Case Western Research Collaboration.

PLoS One. 2010 Feb 22;5(2):e9138. doi: 10.1371/journal.pone.0009138.

13.

Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NT, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D.

J Clin Microbiol. 2010 Jan;48(1):229-37. doi: 10.1128/JCM.01463-09. Epub 2009 Oct 28.

14.

Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda.

Ogwang S, Asiimwe BB, Traore H, Mumbowa F, Okwera A, Eisenach KD, Kayes S, Jones-López EC, McNerney R, Worodria W, Ayakaka I, Mugerwa RD, Smith PG, Ellner J, Joloba ML.

BMC Infect Dis. 2009 Aug 26;9:139. doi: 10.1186/1471-2334-9-139.

15.

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC. Epub 2009 Jun 19.

16.

Genome scan of M. tuberculosis infection and disease in Ugandans.

Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD, Leontiev DV, Thompson CL, Cartier KC, Elston RC, Iyengar SK, Boom WH, Whalen CC.

PLoS One. 2008;3(12):e4094. doi: 10.1371/journal.pone.0004094. Epub 2008 Dec 31.

17.

Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis.

Srikantiah P, Wong JK, Liegler T, Walusimbi M, Mayanja-Kizza H, Kayanja HK, Mugerwa RD, Charlebois ED, Boom WH, Whalen CC, Havlir DV.

J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):458-60. doi: 10.1097/QAI.0b013e31817e9fb4. No abstract available.

18.

Whole blood interferon-gamma responses to mycobacterium tuberculosis antigens in young household contacts of persons with tuberculosis in Uganda.

Lewinsohn DA, Zalwango S, Stein CM, Mayanja-Kizza H, Okwera A, Boom WH, Mugerwa RD, Whalen CC.

PLoS One. 2008;3(10):e3407. doi: 10.1371/journal.pone.0003407. Epub 2008 Oct 15.

19.

Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda.

Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, Worodria W, Levin J, Joloba M, Okwera A, Eisenach KD, McNerney R, Elliott AM, Smith PG, Mugerwa RD, Ellner JJ, Jones-López EC.

Clin Infect Dis. 2008 Nov 1;47(9):1126-34. doi: 10.1086/592252.

20.

Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.

Srikantiah P, Walusimbi MN, Kayanja HK, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV.

AIDS. 2007 Sep 12;21(14):1972-4.

21.

Men's circumcision status and women's risk of HIV acquisition in Zimbabwe and Uganda.

Turner AN, Morrison CS, Padian NS, Kaufman JS, Salata RA, Chipato T, Mmiro FA, Mugerwa RD, Behets FM, Miller WC.

AIDS. 2007 Aug 20;21(13):1779-89.

22.

Linkage and association analysis of candidate genes for TB and TNFalpha cytokine expression: evidence for association with IFNGR1, IL-10, and TNF receptor 1 genes.

Stein CM, Zalwango S, Chiunda AB, Millard C, Leontiev DV, Horvath AL, Cartier KC, Chervenak K, Boom WH, Elston RC, Mugerwa RD, Whalen CC, Iyengar SK.

Hum Genet. 2007 Jul;121(6):663-73. Epub 2007 Apr 13.

PMID:
17431682
23.

Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda.

Traore H, Ogwang S, Mallard K, Joloba ML, Mumbowa F, Narayan K, Kayes S, Jones-Lopez EC, Smith PG, Ellner JJ, Mugerwa RD, Eisenach KD, McNerney R.

Ann Clin Microbiol Antimicrob. 2007 Jan 9;6:1.

24.

Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country.

Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, Mugerwa RD, Boom H, Eisenach KD, Joloba ML.

Int J Tuberc Lung Dis. 2006 Nov;10(11):1262-7.

PMID:
17131786
25.

Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults.

Lim HJ, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC.

HIV Clin Trials. 2006 Jul-Aug;7(4):172-83.

26.

Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda.

Whalen CC, Chiunda A, Zalwango S, Nshuti L, Jones-Lopez E, Okwera A, Hirsch C, Peters P, Boom WH, Mugerwa RD.

Am J Trop Med Hyg. 2006 Jul;75(1):55-61.

27.

Stevens - Johnson syndrome due to nevirapine.

Namayanja GK, Nankya JM, Byamugisha JK, Ssali FN, Kityo CM, Rwambuya SD, Mugerwa RD, Mmiro FA, Morrison CS, Salata RA.

Afr Health Sci. 2005 Dec;5(4):338-40.

28.

Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.

Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL, Nunn P, Ellner JJ, Whalen CC, Mugerwa RD.

Int J Tuberc Lung Dis. 2006 Jan;10(1):39-44.

29.

Delayed-type hypersensitivity skin test reactivity and survival in HIV-infected patients in Uganda: should anergy be a criterion to start antiretroviral therapy in low-income countries?

Jones-López EC, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC.

Am J Trop Med Hyg. 2006 Jan;74(1):154-61.

PMID:
16407361
30.

Vdelta2+ gammadelta T cell function in Mycobacterium tuberculosis- and HIV-1-positive patients in the United States and Uganda: application of a whole-blood assay.

Rojas RE, Chervenak KA, Thomas J, Morrow J, Nshuti L, Zalwango S, Mugerwa RD, Thiel BA, Whalen CC, Boom WH.

J Infect Dis. 2005 Nov 15;192(10):1806-14. Epub 2005 Oct 12.

31.

Evidence for a major gene influence on tumor necrosis factor-alpha expression in tuberculosis: path and segregation analysis.

Stein CM, Nshuti L, Chiunda AB, Boom WH, Elston RC, Mugerwa RD, Iyengar SK, Whalen CC.

Hum Hered. 2005;60(2):109-18. Epub 2005 Oct 13.

PMID:
16224188
32.

Mechanisms of apoptosis of T-cells in human tuberculosis.

Hirsch CS, Johnson JL, Okwera A, Kanost RA, Wu M, Peters P, Muhumuza M, Mayanja-Kizza H, Mugerwa RD, Mugyenyi P, Ellner JJ, Toossi Z.

J Clin Immunol. 2005 Jul;25(4):353-64.

PMID:
16133992
33.

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

Mayanja-Kizza H, Jones-Lopez E, Okwera A, Wallis RS, Ellner JJ, Mugerwa RD, Whalen CC; Uganda-Case Western Research Collaboration.

J Infect Dis. 2005 Mar 15;191(6):856-65. Epub 2005 Feb 8.

34.

Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.

Johnson JL, Nunn AJ, Fourie PB, Ormerod LP, Mugerwa RD, Mwinga A, Chintu C, Ngwira B, Onyebujoh P, Zumla A.

Int J Tuberc Lung Dis. 2004 Nov;8(11):1348-54.

PMID:
15581204
35.

The species Mycobacterium africanum in the light of new molecular markers.

Niemann S, Kubica T, Bange FC, Adjei O, Browne EN, Chinbuah MA, Diel R, Gyapong J, Horstmann RD, Joloba ML, Meyer CG, Mugerwa RD, Okwera A, Osei I, Owusu-Darbo E, Schwander SK, Rüsch-Gerdes S.

J Clin Microbiol. 2004 Sep;42(9):3958-62.

36.

Rifampicin-containing regimens for the treatment of latent tuberculosis infection also prevented diarrheal illnesses in HIV-infected Ugandan adults.

Johnson JL, Okwera A, Horter L, Whalen CC, Mugerwa RD; Uganda Case Western Reserve University Research Collaboration.

AIDS. 2004 Mar 5;18(4):706-8. No abstract available.

PMID:
15090784
37.

Burden of tuberculosis in Kampala, Uganda.

Guwatudde D, Zalwango S, Kamya MR, Debanne SM, Diaz MI, Okwera A, Mugerwa RD, King C, Whalen CC.

Bull World Health Organ. 2003;81(11):799-805. Epub 2004 Jan 20.

38.

Tuberculosis in household contacts of infectious cases in Kampala, Uganda.

Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, Mugerwa RD, Ellner JJ, Bukenya G, Whalen CC.

Am J Epidemiol. 2003 Nov 1;158(9):887-98.

39.

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, Mugerwa RD; Uganda-Case Western Reserve University Research Collaboration.

Am J Respir Crit Care Med. 2003 Jul 15;168(2):185-91. Epub 2003 Apr 17.

PMID:
12702550
40.
41.
42.

Mycobacterium africanum subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda.

Niemann S, Rüsch-Gerdes S, Joloba ML, Whalen CC, Guwatudde D, Ellner JJ, Eisenach K, Fumokong N, Johnson JL, Aisu T, Mugerwa RD, Okwera A, Schwander SK.

J Clin Microbiol. 2002 Sep;40(9):3398-405.

43.

First trial of the HIV-1 vaccine in Africa: Ugandan experience.

Mugerwa RD, Kaleebu P, Mugyenyi P, Katongole-Mbidde E, Hom DL, Byaruhanga R, Salata RA, Ellner JJ; HIV-1 Vaccine Trial Group.

BMJ. 2002 Jan 26;324(7331):226-9. Review. No abstract available.

44.

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.

Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC; Uganda-Case Western Reserve University Research Collaboration.

AIDS. 2001 Nov 9;15(16):2137-47.

PMID:
11684933
45.

Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation.

Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, Okwera A, Joloba M, Mugyenyi P, Mugerwa RD, Aung H, Ellner JJ, Hirsch CS.

J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):1-8.

PMID:
11579270
46.

Evaluation of suspected tuberculous pleurisy: clinical and diagnostic findings in HIV-1-positive and HIV-negative adults in Uganda.

Luzze H, Elliott AM, Joloba ML, Odida M, Oweka-Onyee J, Nakiyingi J, Quigley M, Hirsch C, Mugerwa RD, Okwera A, Johnson JL.

Int J Tuberc Lung Dis. 2001 Aug;5(8):746-53.

PMID:
11495266
47.

Quantitative bacillary response to treatment in Mycobacterium tuberculosis infected and M. africanum infected adults with pulmonary tuberculosis.

Joloba ML, Johnson JL, Namale A, Morrissey A, Assegghai AE, Rüsch-Gerdes S, Mugerwa RD, Ellner JJ, Eisenach KD.

Int J Tuberc Lung Dis. 2001 Jun;5(6):579-82.

PMID:
11409588
48.

Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis.

Hirsch CS, Toossi Z, Johnson JL, Luzze H, Ntambi L, Peters P, McHugh M, Okwera A, Joloba M, Mugyenyi P, Mugerwa RD, Terebuh P, Ellner JJ.

J Infect Dis. 2001 Mar 1;183(5):779-88. Epub 2001 Feb 8.

PMID:
11181155
49.

Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.

Johnson JL, Okwera A, Nsubuga P, Nakibali JG, Whalen CC, Hom D, Cave MD, Yang ZH, Mugerwa RD, Ellner JJ.

Int J Tuberc Lung Dis. 2000 Nov;4(11):1032-40.

50.

Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.

Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, Michael NL, Mugerwa RD, Ellner JJ.

AIDS. 2000 Jun 16;14(9):1219-28.

Supplemental Content

Loading ...
Support Center